Registered outcomes27

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 27 of 27

List	Outcome	Time frame
Secondary	Participants with prostate cancer: time to PSA progression (TTPP)	2 years
Secondary	Time to First Subsequent Therapy (TFST)	2 years
Secondary	Overall Survival (OS)	2 years
Secondary	Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)	2 years
Secondary	Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)	2 years
Secondary	Incidence rate of anti-drug antibody (ADA) against ICP-B381	2 years
Secondary	Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE	2 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07901413/registered?page=2